Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.215
+0.005 (0.41%)
At close: Sep 21, 2026, 4:00 PM EDT
1.190
-0.025 (-2.06%)
After-hours: Sep 21, 2026, 4:10 PM EDT
Cocrystal Pharma Employees
Cocrystal Pharma had 10 employees as of December 31, 2025. The number of employees decreased by 1 or -9.09% compared to the previous year.
Employees
10
Change (1Y)
-1
Growth (1Y)
-9.09%
Revenue / Employee
$33,000
Profits / Employee
-$993,800
Market Cap
23.40M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10 | -1 | -9.09% |
| Dec 31, 2024 | 11 | -1 | -8.33% |
| Dec 31, 2023 | 12 | 0 | - |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| Jasper Therapeutics | 22 |
| Atossa Therapeutics | 16 |
| Actuate Therapeutics | 12 |
| Tvardi Therapeutics | 12 |
| Psyence Biomedical | 12 |
| Cellectar Biosciences | 11 |
| Polyrizon | 4 |
COCP News
- 12 days ago - Cocrystal Pharma doses last subject in norovirus challenge study - TheFly
- 12 days ago - Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment - GlobeNewsWire
- 5 weeks ago - Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors - GlobeNewsWire
- 7 weeks ago - Cocrystal Pharma announces $5M investment from Opko Health - TheFly
- 7 weeks ago - Cocrystal Pharma announces $5M private placement with Opko Health - TheFly
- 7 weeks ago - Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health - GlobeNewsWire
- 3 months ago - Cocrystal co-CEOs Sam Lee and Jim Martin step down, James Sapirstein succeeds - TheFly
- 3 months ago - Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer - GlobeNewsWire